SVR12 Rates Higher Than 99% After Sofosbuvir/Velpatasvir Combination in HCV Infected Patients With F0-F1 Fibrosis Stage: A Real World Experience

PLoS ONE - United States
doi 10.1371/journal.pone.0215783
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Sofosbuvir and Velpatasvir: A Complete Pan-Genotypic Treatment for HCV Patients

Turkish Journal of Gastroenterology
Gastroenterology
2016English

Sofosbuvir-Based Therapies for Patients With Hepatitis C Virus Infection: Real-World Experience in China

Canadian Journal of Gastroenterology and Hepatology
MedicineHepatologyGastroenterology
2018English

Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Patients Coinfected With HCV and HIV-1

Journal of Hepatology
Hepatology
2017English

Tolerability and Discontinuation Rates in Teriflunomide-Treated Patients. A Real-World Clinical Experience

Neurosciences
PsychiatryMental HealthNeurology
2018English

Secondary Occult Hepatitis C Virus Infection (HCV) in Chronic HCV Patients After Treatment With Sofosbuvir and Daclatasvir

International Journal of Current Microbiology and Applied Sciences
2018English

Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia

American Journal of Hematology
Hematology
2018English

Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Genotype 3a in Pakistani Population - A Real World Experience

Pakistan Journal of Medical Sciences
Medicine
2019English

Ledipasvir and Sofosbuvir for HCV-infection in Patients Coinfected With HBV

Antiviral Therapy
Infectious DiseasesPharmacology
2016English

A Prospective Study of Daclatasvir and Sofosbuvir in Chronic HCV-infected Kidney Transplant Recipients

BMC Nephrology
Nephrology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy